Proteomics and Metabolomics as Tools to Unravel Novel Culprits and Mechanisms of Uremic Toxicity: Instrument or Hype?

Seminars in Nephrology

Volumn 34, Issue 2, 2014, Pages 180-190

  Mullen, William ^a   Saigusa, Daisuke ^b   Abe, Takaaki ^b,c   Adamski, Jerzy ^d,e,f   Mischak, Harald ^a,g  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b TOHOKU UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g MOSAIQUES DIAGNOSTICS GMBH   (Germany)

Author keywords

Biomarker; Dialysis; Metabolome; Proteome; Uremic toxin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE; CREATININE; GLUCOSE; GLUTAMIC ACID; HYPOXANTHINE; INOSINE; INOSITOL; LACTIC ACID; MALTOSE; N(G),N(G) DIMETHYLARGININE; ORGANIC ANION TRANSPORTER H; PROTEOME; PYRUVIC ACID; SUCCINIC ACID; TRIMETHYLAMINE OXIDE; UREA; UREMIC TOXIN; TOXIN;

CAPILLARY ELECTROPHORESIS; CARBON NUCLEAR MAGNETIC RESONANCE; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; RENAL REPLACEMENT THERAPY; REPRODUCIBILITY; REVIEW; TWO DIMENSIONAL ELECTROPHORESIS; UREMIA; FORECASTING; KIDNEY FAILURE, CHRONIC; MEDICAL RESEARCH;

BIOMEDICAL RESEARCH; FORECASTING; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLOMICS; PROTEOMICS; TOXINS, BIOLOGICAL; UREMIA;

EID: 84899048873     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.02.009     Document Type: Review

References (79)

1. Duranton F., Cohen G., De S.R., Rodriguez M., Jankowski J., Vanholder R., et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012, 23:1258-1270.
2. Duranton F., Depner T.A., Argilés A. The saga of two centuries of urea: non-toxic toxin or vice versa?. Semin Nephrol 2014, 34:87-96.
3. Schepers E., Speer T., Fliser D., Kielstein J.T. The dimethylarginines ADMA and SDMA and other guanidines: the real water soluble small toxins?. Semin Nephrol 2014, 34:97-105.
4. Sirich T., Meyer T.W., Gondouin B., Brunet P., Niwa T. Protein-bound molecules: a large family with a bad character. Semin Nephrol 2014, 34:106-117.
5. Chmielewski M., Cohen G., Wiecek A., Carrero J.J. The peptidic middle molecules: is molecular weight doing the trick?. Semin Nephrol 2014, 34:180-190.
6. Jankowski J., Westhof T., Vaziri N.D., Ingrosso D., Perna A. Gasses as uremic toxins: is there something in the air?. Semin Nephrol 2014, 34:135-150.
7. Nicholson J.K., Holmes E., Kinross J.M., Darzi A.W., Takats Z., Lindon J.C. Metabolic phenotyping in clinical and surgical environments. Nature 2012, 491:384-392.
8. Psychogios N., Hau D.D., Peng J., Guo A.C., Mandal R., Bouatra S., et al. The human serum metabolome. PLoS One 2011, 6:e16957.
9. Pan Z., Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007, 387:525-527.
10. Zhao Y.Y. Metabolomics in chronic kidney disease. Clin Chim Acta 2013, 422:59-69.
11. A J., Trygg J., Gullberg J., Johansson A.I., Jonsson P., Antti H., et al. Extraction and GC/MS analysis of the human blood plasma metabolome. Anal Chem 2005, 77:8086-8094.
12. Xiao J.F., Varghese R.S., Zhou B., Nezami Ranjbar M.R., Zhao Y., Tsai T.H., et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res 2012, 11:5914-5923.
13. Soga T., Ohashi Y., Ueno Y., Naraoka H., Tomita M., Nishioka T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2003, 2:488-494.
14. Glauser G., Veyrat N., Rochat B., Wolfender J.L., Turlings T.C. Ultra-high pressure liquid chromatography-mass spectrometry for plant metabolomics: a systematic comparison of high-resolution quadruple-time-of-flight and single stage Orbitrap mass spectrometers. J Chromatogr A. 2013, 1292:151-159.
15. Becker S., Kortz L., Helmschrodt C., Thiery J., Ceglarek U. LC-MS-based metabolomics in the clinical laboratory. J Chromatogr B Analyt Technol Biomed Life Sci. 2012, 883-884. :68-75.
16. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009, 15:431-440.
17. Want E.J., Nordstrom A., Morita H., Siuzdak G. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res 2007, 6:459-468.
18. Suhre K., Shin S.Y., Petersen A.K., Mohney R.P., Meredith D., Wagele B., et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011, 477:54-60.
19. Gika H.G., Theodoridis G.A., Wingate J.E., Wilson I.D. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res 2007, 6:3291-3303.
20. Goek O.N., Doring A., Gieger C., Heier M., Koenig W., Prehn C., et al. Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis 2012, 60:197-206.
21. Artati A, Prehn C, Moller G, Adamski J. Assay tools for metabolomics. In: Suhre K, ed. Genetics meets metabolomics: from experiment to systems biology. New York, Springer; 2012, pp 13-38.
22. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007, 26:51-78.
23. Serkova N.J., Niemann C.U. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics. Expert Rev Mol Diagn 2006, 6:717-731.
24. McLerran D., Grizzle W.E., Feng Z., Thompson I.M., Bigbee W.L., Cazares L.H., et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008, 54:53-60.
25. Kolch W., Mischak H., Pitt A.R. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond) 2005, 108:369-383.
26. Fliser D., Novak J., Thongboonkerd V., Argiles A., Jankowski V., Girolami M., et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007, 18:1057-1071.
27. Mischak H., Coon J.J., Novak J., Weissinger E.M., Schanstra J.P., Dominiczak A.F. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 2009, 28:703-724.
28. Dakna M., He Z., Yu W.C., Mischak H., Kolch W. Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1250-1258.
29. Mischak H., Massy Z.A., Jankowski J. Proteomics in uremia and renal disease. Semin Dial 2009, 22:409-416.
30. Pieper R., Gatlin C.L., Makusky A.J., Russo P.S., Schatz C.R., Miller S.S., et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003, 3:1345-1364.
31. You S.A., Wang Q.K. Proteomics with two-dimensional gel electrophoresis and mass spectrometry analysis in cardiovascular research. Methods Mol Med 2006, 129:15-26.
32. Oh-Ishi M., Maeda T. Disease proteomics of high-molecular-mass proteins by two-dimensional gel electrophoresis with agarose gels in the first dimension (Agarose 2-DE). J Chromatogr B Analyt Technol Biomed Life Sci 2007, 849:211-222.
33. Molin L., Seraglia R., Lapolla A., Ragazzi E., Gonzalez J., Vlahou A., et al. A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. J Proteomics 2012, 75:5888-5897.
34. Albalat A., Stalmach A., Bitsika V., Siwy J., Schanstra J.P., Petropoulos A.D., et al. Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. Proteomics 2013, 13:2967-2975.
35. Mischak H., Schiffer E., Zürbig P., Dakna M., Metzger J. Urinary proteome analysis using capillary electrophoresis coupled mass spectrometry: a powerful tool in clinical diagnosis, prognosis and therapy evaluation. J Med Biochem 2009, 28:223-234.
36. Mischak H., Schanstra J.P. CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl 2011, 5:9-23.
37. Albalat A., Mischak H., Mullen W. Clinical application of urinary proteomics/peptidomics. Expert Rev Proteomics 2011, 8:615-629.
38. Stalmach A., Albalat A., Mullen W., Mischak H. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 2013, 34:1452-1464.
39. Good D.M., Zürbig P., Argiles A., Bauer H.W., Behrens G., Coon J.J., et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010, 9:2424-2437.
40. Jantos-Siwy J., Schiffer E., Brand K., Schumann G., Rossing K., Delles C., et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009, 8:268-281.
41. Mullen W., Albalat A., Gonzalez J., Zerefos P., Siwy J., Franke J., et al. Performance of different separation methods interfaced in the same MS-reflection TOF detector: a comparison of performance between CE versus HPLC for biomarker analysis. Electrophoresis 2012, 33:567-574.
42. Mischak H., Kolch W., Aivalotis M., Bouyssie D., Court M., Dihazi H., et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 2010, 4:464-478.
43. Mischak H., Allmaier G., Apweiler R., Attwood T., Baumann M., Benigni A., et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010, 2:46ps42.
44. Dunn W.B., Broadhurst D., Begley P., Zelena E., Francis-McIntyre S., Anderson N., et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011, 6:1060-1083.
45. Dakna M., Harris K., Kalousis A., Carpentier S., Kolch W., Schanstra J.P., et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 2010, 11:594.
46. Vlahou A. Back to the future in bladder cancer research. Expert Rev Proteomics 2011, 8:295-297.
47. Floegel A., Drogan D., Wang-Sattler R., Prehn C., Illig T., Adamski J., et al. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS One 2011, 6:e21103.
48. Kaiser T., Hermann A., Kielstein J.T., Wittke S., Bartel S., Krebs R., et al. Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids. J Chromatogr A. 2003, 1013:157-171.
49. Ward R.A., Brinkley K.A. A proteomic analysis of proteins removed by ultrafiltration during extracorporeal renal replacement therapy. Contrib Nephrol 2004, 141:280-291.
50. Molina H., Bunkenborg J., Reddy G.H., Muthusamy B., Scheel P.J., Pandey A. A proteomic analysis of human hemodialysis fluid. Mol Cell Proteomics 2005, 4:637-650.
51. Weissinger E.M., Kaiser T., Meert N., De Smet R., Walden M., Mischak H., et al. Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant 2004, 19:3068-3077.
52. Dihazi H., Muller C.A., Mattes H., Muller G.A. Proteomic analysis to improve adequacy of hemo- and peritoneal dialysis: removal of small and high molecular weight proteins with high- and low-flux filters or a peritoneal membrane. Proteomics Clin Appl 2008, 2:1167-1182.
53. Tattersall J., Canaud B., Heimburger O., Pedrini L., Schneditz D., Van B.W. High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study. Nephrol Dial Transplant 2010, 25:1230-1232.
54. Liabeuf S., Neirynck N., Drüeke T.B., Vanholder R., Massy Z.A. Clinical studies and uremia: what did we learn recently?. Semin Nephrol 2014, 34:164-179.
55. Hallbauer J., Kreusch S., Klemm A., Wolf G., Rhode H. Long-term serum proteomes are quite similar under high- and low-flux hemodialysis treatment. Proteomics Clin Appl 2010, 4:953-961.
56. Lin Y.P., Yang C.Y., Liao C.C., Yu W.C., Chi C.W., Lin C.H. Plasma protein characteristics of long-term hemodialysis survivors. PLoS One 2012, 7:e40232.
57. Mange A., Goux A., Badiou S., Patrier L., Canaud B., Maudelonde T., et al. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PLoS One 2012, 7:e34107.
58. Zieske L.R. A perspective on the use of iTRAQ (TM) reagent technology for protein complex and profiling studies. J Exp Bot 2006, 57:1501-1508.
59. Galli F. Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant 2007, 22(Suppl 5):v20-v36.
60. Rossing K., Mischak H., Rossing P., Schanstra J.P., Wiseman A., Maahs D.M. The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008, 2:997-1007.
61. Rossing K., Mischak H., Dakna M., Zürbig P., Novak J., Julian B.A., et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290.
62. Tan A.L., Forbes J.M., Cooper M.E. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007, 27:130-143.
63. Maahs D.M., Siwy J., Argiles A., Cerna M., Delles C., Dominiczak A.F., et al. Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One 2010, 5:e13051.
64. Roscioni S.S., de Zeeuw D., Hellemons M.E., Mischak H., Zurbig P., Bakker S.J., et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 2013, 56:259-267.
65. Zürbig P., Jerums G., Hovind P., MacIsaac R., Mischak H., Nielsen S.E., et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 2012, 61:3304-3313.
66. Argiles A., Siwy J., Duranton F., Gayrard N., Dakna M., Lundin U., et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013, 8:e62837.
67. Toyohara T., Akiyama Y., Suzuki T., Takeuchi Y., Mishima E., Tanemoto M., et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res 2010, 33:944-952.
68. Toyohara T., Suzuki T., Morimoto R., Akiyama Y., Souma T., Shiwaku H.O., et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 2009, 20:2546-2555.
69. Saigusa D., Suzuki N., Takahashi M., Shiba K., Tanaka S., Abe T., et al. Simultaneous determination of guanidinosuccinic acid and guanidinoacetic acid in urine using high performance liquid chromatography/tandem mass spectrometry. Anal Chim Acta 2010, 677:169-175.
70. Spector T.D., Williams F.M. The UK adult twin registry (TwinsUK). Twin Res Hum Genet 2006, 9:899-906.
71. Illig T., Gieger C., Zhai G., Romisch-Margl W., Wang-Sattler R., Prehn C., et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010, 42:137-141.
72. Choi J.Y., Yoon Y.J., Choi H.J., Park S.H., Kim C.D., Kim I.S., et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant 2011, 26:1304-1313.
73. Aronov P.A., Luo F.J., Plummer N.S., Quan Z., Holmes S., Hostetter T.H., et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011, 22:1769-1776.
74. Meijers B., Glorieux G., Poesen R., Bakker S. Non-extracorporeal methods for decreasing uremic solute concentration: a future way to go?. Semin Nephrol 2014, 34:228-243.
75. Suhre K., Meisinger C., Doring A., Altmaier E., Belcredi P., Gieger C., et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One 2010, 5:e13953.
76. Rhee E.P., Souza A., Farrell L., Pollak M.R., Lewis G.D., Steele D.J., et al. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 2010, 21:1041-1051.
77. Mischak H., Ioannidis J.P., Argiles A., Attwood T.K., Bongcam-Rudloff E., Broenstrup M., et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 2012, 42:1027-1036.
78. Perco P., Wilflingseder J., Bernthaler A., Wiesinger M., Rudnicki M., Wimmer B., et al. Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. J Cell Mol Med 2008, 12:1177-1187.
79. Molina F., Dehmer M., Perco P., Graber A., Girolami M., Spasovski G., et al. Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant 2010, 25:1015-1018.